First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

Clinical trial NCT05745350 · RECRUITING

Trial details

NCT number: NCT05745350
Sponsor: Xiaorong Dong
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Small Cell Lung Cancer Extensive Stage

Start date: 2024-03-07
Primary completion: 2025-06-01
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.